Tommaso De Pas

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Dong-Wan Kim, Ranee Mehra et al. · New England Journal of Medicine · 2014 · 1.4K citations · Full text

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa et al. · The Lancet Oncology · 2016 · 489 citations · Full text

Oncology, Immunology, Bronchial Neoplasm +8

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan et al. · The Lancet Oncology · 2016 · 467 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, Egbert F. Smit, David Planchard et al. · Annals of Oncology · 2015 · 355 citations · Full text

Non-small-cell Lung Cancer, Medicine, Pharmacology +10